philia B drug Alprolix (coagulation factor IX (Recombinant), Fc fusion protein). In its suit, filed yesterday, March 4, at the US District Court for the District of Delaware, the Sanofi subsidiary accused CSL of infringing US patent numbers 10,548,954; 10,561,714; and 10,568,943, all of which cover "Factor IX polypeptid

olely in the courts of the State of Delaware or (to the extent subject matter jurisdiction exists therefor) of the United States District Court for the District of Delaware, and the parties irrevocably submit to the exclusive jurisdiction of such courts in respect of any such action or proceeding. 3 DocL USI:10492642v

ition, on September 1, 2015, Haggen commenced a lawsuit against Albertson's LLC and Albertson's Holdings LLC in the United States District Court for the District of Delaware, alleging claims for violation of Section 7 of the Clayton Act, attempted monopolization under the Sherman Act, breath of contract, indemnification,

in the future. On September 8, 2015, Haggen commenced a case under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware, and on September 14, 2015, Haggen filed a motion in its bankruptcy case for an order authorizing and approving procedures for the rejection of unex

n has further moved to transfer the lawsuit the Company commenced in Superior Court of the State of Delaware to the United States District Court for the District of Delaware. The Company's Delaware state court case is now stayed due to Haggen's Chapter 11 bankruptcy case. The Company believes that the claims asserted by

unty. On September 1, 2015, Haggen commenced a lawsuit against Albertson's LLC and Albertson's Holdings LLC in the United States District Court for the District of Delaware. alleging claims for violation of Section 7 of the Clayton Act, attempted monopolization under the Sherman Act, breach of contract, indemnification,

the State of Delaware (or. only if such court declines to accept jurisdiction over a particular matter, then of the United States District Court for the District of Delaware. or if jurisdiction is not then available in the United States District Court for the District of Delaware (but only in such event), then of any De

urt located within the State of Delaware, or if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware, shall be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary dut